SavedAdd your journal

Journals / Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi / 2015 / Cilt: 2 - Sayı: 1

NODÜLER LENFOSİT BASKIN HODGKİN LENFOMA TEDAVİSİ

Zafer Gökgöz
Ali İhsan GEMİCİ
İsmet Aydoğdu
Pages
8–10
Publication Date
2015-07-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We will discuss the treatment of the disease in the light of the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nodular lymphocyte predominate Hodgkin Lymphoma (NLPHL) is a rare subtype of Hodgkin Lymphoma.
📊
Key Findings & Data:Disease is generally nonaggressive and asymptomatic except peripheral lymphadenomegaly.
💡
Conclusion & Impact:We will discuss the treatment of the disease in the light of the literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Nodüler Lenfosit Predominant Hodgkin Lenfoma · Noduler Lymphocyte Predominate Hodgkin Lymphoma

Abstract

Nodular lymphocyte predominate Hodgkin Lymphoma (NLPHL) is a rare subtype of Hodgkin Lymphoma. Disease is generally nonaggressive and asymptomatic except peripheral lymphadenomegaly. Cots-Wolds modified Ann Arborsystem is used for staging. Treatment of NLPHL consists of chemotherapy, radiotherapy or combination of both. We will discuss the treatment of the disease in the light of the literature.

Özet

Nodüler lenfosit baskın Hodgkin Lenfoma (NLBHL) nadir görülen bir Hodgkin Lenfoma alt tipidir. Genel olarak saldırgan bir seyir göstermeyen hastalık, sıklıkla periferal lenfadenomegaliler dışında asemptomatiktir. Hodgkin Lenfoma gibi Cots-Wolds modifikasyonuyla Ann-Arbor evreleme sistemine göre evrelenir. Tedavide kemoterapi ve radyoterapi ya da bunların kombinasyonları kullanılabilir. Bu derlemede NLBHL'nin çalışmalar eşliğinde tedavisinden bahsedeceğiz.

🔖

Cite This Article

Gökgöz, Z., GEMİCİ, A. İ., Aydoğdu, İ. (2015). NODÜLER LENFOSİT BASKIN HODGKİN LENFOMA TEDAVİSİ. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, Cilt: 2 - Sayı: 1, 8–10. https://ajindex.com/articles/714346

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe bymorphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724. Braeuninger A, Küppers R, Strickler JG, et al. Hodgkin and Reed Sternbergcells in lymphocyte predominant Hodgkin diseasere present clonal populations of germinal center- derived tumor B cells. ProcNatl Acad Sci USA. 1997;94:9337. 4. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin'sdisease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337:453. Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med. 1997;337:459 Schmitz R, Stanelle J, Hansmann ML, Küppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol. 2009;4:151. Mauch PM, Kalish LA, Kadin M, et al. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer. 1993;71:2062.
  2. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the EuropeanTask Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999;17:776. Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Grouptrials. J ClinOncol. 2005;23:5739. National Comprehensive Cancer Network (NCCN 2.2015). NCCN http://www.nccn.org/professionals/physician_gls/f_guidelines. asp Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte- predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 2010;28:136. Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 2005;104:1221. Nogová L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte- predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgki